BLMK ICB Direct Oral Anticoagulant (DOAC) Medication Review Service

Concepts

• general practitioner
• bedfordshire
• health services
• undertaken similar doac review
• doac prescribing
• blmk icb direct oral anticoagulant
• provider employed non-medical prescribing pharmacist
• blmk
• direct award process a
• a high quality and safe doac review

Location

All ICB's geographical regions i.e. Bedfordshire, Luton and Milton Keynes

Description

The Direct Oral Anticoagulant (DOAC) medication review service will assist Bedfordshire, Luton and Milton Keynes (BLMK) GP practices to deliver a high quality and safe DOAC review and change programme.

Total Quantity or Scope

The Direct Oral Anticoagulant (DOAC) medication review service will be delivered by provider employed non-medical prescribing pharmacist with clinical expertise in DOAC prescribing and experience of undertaken similar DOAC review and change programmes. Identifying, reviewing and where appropriate and with patients consent initiating/prescribing a cost-effective DOAC for the patient. The contact has been awarded following direct award process A with a maximum contract value £165,000 based on £550 per clinical day (7.5hrs) and the contract value is activity related. The contract is for a period of 4 months from 1st September 2025 to 31st December 2025 with an option to extend for a period of up to 3months i.e. 31st March 2026, if required within the specified financial envelope.

Award Detail

Award Criteria

CPV Codes

• 85121100 - General-practitioner services
• 85100000 - Health services

Indicators

• Award on basis of price.

Legal Justification

No realistic alternative provider.

Other Information

This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.There is a risk of a significant cost pressure to the BLMK ICB prescribing budget through the anticipated loss of a commercial agreement within direct oral anticoagulants (DOACs) prescribing. As a risk mitigation, people on edoxaban within BLMK will be reviewed and where clinically appropriate and with patient consent changed to the most cost-effective DOACs, as identified in NHSE DOAC Commissioning Guidance.An additional financial risks exists to the BLMK ICB prescribing budget if the review and change programme does not happen at the scale and pace that is required to mitigate loss of the commercial agreement. GP pressures and workforce capacity limitations, means a 3rd party clinical provider with expertise in DOAC prescribing and experience of safely undertaking a DOAC review and change programme is required. Due to the imminent cost pressure there is a need to mobilise the service by 1st September 2025.The BLMK ICB Chiefs (Executives) gave approval of this in August 2025 at the scheduled Investment Oversight Group Meeting. Conflicts of interest have been managed in line with the ICB's Conflict of Interest and Standards of Business Conduct Policy.